Ranibizumab Approved in EU For Vision Loss Due to Diabetic Macular Edema

The European Medicines Agency (EMEA) has granted Novartis (Basel, Switzerland) a new, broader indication for ranibizumab (Lucentis, Genentech) to treat patients with visual impairment due to diabetic macular edema (DME), according to a company news release. The approval was based on data from two Novartis-sponsored cl...

Full Story →